ASLAN Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients.
ASLAN is currently evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease. ASLAN has a team in Menlo Park, California, and in Singapore.
For additional information please visit www.aslanpharma.com.
Location: Singapore
Employees: 51-200
Total raised: $150M
Founded date: 2010
Investors 2
| Date | Name | Website |
| - | K2 HealthV... | k2healthve... |
| - | K2 HealthV... | k2hv.com |
Funding Rounds 5
| Date | Series | Amount | Investors |
| 12.03.2024 | - | $5M | - |
| 13.07.2021 | - | $45M | - |
| 04.07.2016 | Pre-IPO | $23M | - |
| 07.01.2016 | Series C | $43M | - |
| 08.12.2015 | Series C | $34M | - |
Mentions in press and media 25
| Date | Title | Description | Source |
| 13.03.2024 | ASLAN Pharmaceuticals Secures $5 Million in Direct Offering | ASLAN Pharmaceuticals, a biopharmaceutical company on a mission to revolutionize patient care, has c... | parsers.vc... |
| 12.03.2024 | ASLAN Pharmaceuticals Announces $5 Million Registered Direct... | SAN MATEO, Calif. and SINGAPORE, March 12, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd. (Nasd... | einpresswi... |
| 12.03.2024 | ASLAN Pharmaceuticals Announces $5 Million Registered Direct... | - | globenewsw... |
| 06.03.2024 | ASLAN Pharmaceuticals Announces New Translational Data on Eb... | - | globenewsw... |
| 28.10.2022 | ASLAN Pharmaceuticals Reports Third Quarter 2022 Financial R... | Company maintains healthy operating position with US$68.9 million in cash, cash equivalents and shor... | einpresswi... |
| 21.01.2022 | Accompanying slides, A4 KOL Series: Episode 2, Dr April Arms... | ASLAN A4 Series: Aspects of Atopic Dermatitis and ASLAN004 with Dr April Armstrong 20 January 2022 N... | marketscre... |
| 21.01.2022 | ASLAN Pharmaceuticals : Company Presentation January 2022 | Company presentation January 2022 NASDAQ: ASLN 1 Legal disclaimer This presentation contains forward... | marketscre... |
| 10.01.2022 | ASLAN Pharmaceuticals : Company Presentation January 2022 | Company presentation January 2022 NASDAQ: ASLN 1 Legal disclaimer This presentation contains forward... | marketscre... |
| 01.12.2021 | ASLAN Pharmaceuticals : Company Presentation November 2021 | Company presentation November 2021 NASDAQ: ASLN 1 Legal disclaimer This presentation contains forwar... | marketscre... |
| 22.11.2021 | ASLAN Pharmaceuticals Announces Participation at Two Upcomin... | MENLO PARK, Calif. and SINGAPORE, Nov. 22, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: A... | marketscre... |
Show more